ValuEngine upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a sell rating to a hold rating in a report released on Monday, April 2nd.
Several other equities research analysts also recently commented on ADAP. BidaskClub cut shares of Adaptimmune Therapeutics from a hold rating to a sell rating in a report on Wednesday, December 20th. Leerink Swann started coverage on shares of Adaptimmune Therapeutics in a report on Friday, March 16th. They set a buy rating and a $15.00 target price for the company. Finally, Zacks Investment Research cut shares of Adaptimmune Therapeutics from a hold rating to a sell rating in a report on Monday, March 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $11.58.
ADAP stock traded down $0.02 during trading on Monday, hitting $12.34. 320,080 shares of the company’s stock traded hands, compared to its average volume of 630,461. The firm has a market cap of $1,166.44, a price-to-earnings ratio of -15.24 and a beta of 1.16. Adaptimmune Therapeutics has a 1 year low of $4.28 and a 1 year high of $13.41.
In other Adaptimmune Therapeutics news, Director David M. Mott purchased 571,164 shares of the stock in a transaction that occurred on Monday, March 26th. The shares were purchased at an average cost of $1.90 per share, for a total transaction of $1,085,211.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Orbimed Advisors Llc sold 1,048,067 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $11.50, for a total transaction of $12,052,770.50. The disclosure for this sale can be found here. Insiders have bought 9,385,254 shares of company stock valued at $17,966,655 in the last three months. Corporate insiders own 24.45% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC boosted its position in Adaptimmune Therapeutics by 322.2% during the third quarter. Citadel Advisors LLC now owns 83,423 shares of the biotechnology company’s stock worth $683,000 after acquiring an additional 63,664 shares during the last quarter. Graticule Asia Macro Advisors LLC acquired a new position in Adaptimmune Therapeutics during the third quarter worth about $3,242,000. Alps Advisors Inc. boosted its position in Adaptimmune Therapeutics by 12.7% during the fourth quarter. Alps Advisors Inc. now owns 103,816 shares of the biotechnology company’s stock worth $693,000 after acquiring an additional 11,716 shares during the last quarter. Creative Planning boosted its holdings in Adaptimmune Therapeutics by 66.7% in the 4th quarter. Creative Planning now owns 66,681 shares of the biotechnology company’s stock valued at $445,000 after purchasing an additional 26,681 shares during the last quarter. Finally, Artal Group S.A. boosted its holdings in Adaptimmune Therapeutics by 40.0% in the 4th quarter. Artal Group S.A. now owns 700,000 shares of the biotechnology company’s stock valued at $4,676,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 55.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ValuEngine Upgrades Adaptimmune Therapeutics (NASDAQ:ADAP) to “Hold”” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://stocknewstimes.com/2018/04/17/adaptimmune-therapeutics-adap-raised-to-hold-at-valuengine.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.